Dhansa Labs Limited reported a 15.47% increase in Profit After Tax (PAT) to ₹552.26 lakh for the financial year ended March 31, 2026, compared to ₹478.27 lakh in the previous year. Revenue from operations rose 7.82% to ₹14,153.72 lakh from ₹13,126.99 lakh in FY25. The company’s EBITDA stood at ₹1,221.80 lakh, reflecting a growth of 6.31%, with an EBITDA margin of 8.55% and a PAT margin of 3.87%.

Financial Performance

The Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026. For the quarter ended March 31, 2026, net profit was ₹208.94 lakh, while revenue from operations was ₹4,053.73 lakh. Total income for the year increased to ₹14,284.68 lakh from ₹13,318.60 lakh in the prior year. The finance cost for the six months ended March 31, 2026, was reduced by ₹58.94 lakh due to the reversal of costs previously recognized that should have been capitalised.

Capital Allocation and Warrants

During FY26, the company allotted 1,08,69,565 convertible equity warrants on a preferential basis at an issue price of ₹46 per warrant, aggregating to ₹4,999.99 lakh. The company received ₹1,697.50 lakh towards warrant subscription as of March 31, 2026. These funds were fully utilized for general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure, and land-related advances. There was no deviation in the utilization of funds raised.

Strategic Initiatives and Subsidiaries

The company is undertaking a significant capacity expansion initiative aimed at strengthening its manufacturing capabilities, including the planned introduction of Atrazine manufacturing. This project has the potential to contribute approximately ₹120–140 crore in additional annual revenue. Dhansa Labs is also diversifying through its subsidiaries, Dhansa Green Energy Private Limited and Dhansa Biofuels Power Private Limited. Dhansa Green Energy is progressing towards the commissioning of a Compressed Biogas (CBG) project with a capacity of 15 tonnes per day and is developing a Napier Grass project in the Bundi district of Rajasthan. Dhansa Biofuels Power is focused on developing biomass pellets as an alternative to coal.

Auditor’s Report and Compliance

Statutory auditors M/s Kapish Jain & Associates issued an audit report with an unmodified opinion on the audited financial results. The company assessed the impact of the New Labour Codes, effective from November 21, 2025, and recognized an incremental liability of ₹9.46 lakh pertaining to gratuity and leave encashment within employee benefit expenses. The consolidated financial results include the performance of its subsidiaries.

Ambey Laboratories Limited, now operating as Dhansa Labs Limited, has informed stock exchanges that its wholly owned subsidiary, Dhansa Biofuels Power Private Limited, has entered into an agreement for the acquisition of land in Rajasthan. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was intimated to the National Stock Exchange of India Ltd. on 8th May, 2026.

Land Acquisition Details

The acquired land is situated at Khasra Nos. 506 and 519, located in Village Roteda, Tehsil Keshoraipatan, District Bundi, Rajasthan – 323301. The parcel admeasures a total area of approximately 14.32 Bigha and was acquired from Mrs. Rami Bai. The transaction is structured as an all-cash consideration settled through banking channels, with the agreement dated 7th May, 2026.

The following table summarises the key details of the acquisition as disclosed under Annexure A of the regulatory filing:

Strategic Intent and Sector Alignment

The acquisition is stated to be in line with the strategic expansion plans of Dhansa Biofuels Power Private Limited in the renewable energy sector. The land will be held by Dhansa Biofuels for the establishment of a Biogas Pellet Project, reflecting the subsidiary's focus on renewable energy infrastructure.

The company has confirmed that the acquisition does not fall within the definition of a related party transaction. Additionally, promoters, promoter group, and group companies have no interest in the transaction, and it has been conducted at arm's length.

Regulatory Compliance

The intimation was signed by Himanshu Kukreja, Company Secretary and Compliance Officer (Membership No: A64853), on behalf of Dhansa Labs Limited. The disclosure was made in accordance with Regulation 30 read with Schedule III of the SEBI Listing Regulations, and the SEBI Master Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026. The company has also stated that this intimation will be made available on its website at https://ambeylab.com/regulation-30/ .